The ubiquitin-proteasome pathway in cancer

Br J Cancer. 1998;77(3):448-55. doi: 10.1038/bjc.1998.71.

Abstract

Degradation by the 26S proteasome of specific proteins that have been targeted by the ubiquitin pathway is the major intracellular non-lysosomal proteolytic mechanism and is involved in a broad range of processes, such as cell cycle progression, antigen presentation and control of gene expression. Recent work, reviewed here, has shown that this pathway is often the target of cancer-related deregulation and can underlie processes, such as oncogenic transformation, tumour progression, escape from immune surveillance and drug resistance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antigen Presentation
  • Cell Cycle Proteins*
  • Cyclin-Dependent Kinase Inhibitor p27
  • Cysteine Endopeptidases / metabolism*
  • Drug Resistance, Neoplasm
  • Genes, p53 / physiology
  • Humans
  • Microfilament Proteins
  • Microtubule-Associated Proteins / analysis
  • Multienzyme Complexes / metabolism*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Neoplasms / metabolism*
  • Papillomaviridae / genetics
  • Prognosis
  • Proteasome Endopeptidase Complex
  • Transcription Factors / physiology
  • Tumor Suppressor Proteins*
  • Ubiquitins / metabolism*

Substances

  • Cell Cycle Proteins
  • Microfilament Proteins
  • Microtubule-Associated Proteins
  • Multienzyme Complexes
  • Transcription Factors
  • Tumor Suppressor Proteins
  • Ubiquitins
  • Cyclin-Dependent Kinase Inhibitor p27
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex